Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0059 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0059 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0029 | 0 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0059 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0059 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0059 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0052 | 0.7743 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0037 | 0.2407 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0059 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0059 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0037 | 0.2407 | 0.2407 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0059 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.003 | 0.0151 | 0.0151 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0029 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0052 | 0.7743 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0059 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0059 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0059 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0059 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0059 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0059 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0059 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0059 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0059 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.37 uM | Inhibition of recombinant human nNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 0.69 uM | Inhibition of recombinant human nNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 0.71 uM | Inhibition of recombinant human nNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 0.91 uM | Inhibition of recombinant human nNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 1.09 uM | Inhibition of recombinant human iNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 1.17 uM | Inhibition of recombinant human iNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 1.8 uM | Inhibition of recombinant human iNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 4.75 uM | Inhibition of recombinant human iNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 36.7 uM | Inhibition of recombinant human eNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 51.7 uM | Inhibition of recombinant human eNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 53.7 uM | Inhibition of recombinant human eNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
IC50 (binding) | = 124 uM | Inhibition of recombinant human eNOS expressed in baculovirus-infected Sf9 cells assessed as conversion of [3H]-larginine to [3H]-L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting | ChEMBL. | 22840695 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.